Fig. 6: DHODH inhibition changes the metabolic profile in CML CD34+ cells.
From: Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
A shows altered metabolites following treatment of CML CD34+ (n:5) with Meds433 for 3 days. B represents the micromolar concentration of some metabolites in treated and untreated CML CD34+ cells (these metabolites were selected based on their relevance to different biological effects caused by Meds433). C shows the relative mRNA level of DDIT3, p21, and GPT1 in K562 cells treated with 100 nM Meds433 and 1 µM BQ for 3 days (n:3). D shows the relative mRNA level of GPT1 in treated CML CD34+ (n:5) patients’ cells for 3 days. E–G show the percentage of CD11c (n:4), ROS (n:4) production, and cell viability (n:3) in K562 and GPT1 overexpressed K562 after 3 days, respectively. Also, corresponding flow cytometry graphs of CD11c and ROS are shown. H, I demonstrate Pyruvate levels based on RFU in the supernatant and cell lysate of K562 and GPT1 overexpressed K562 after 2 and 3 days of the treatment, respectively. In E, F, H, and I, K562- and GPT1-treated Meds433 were not compared due to different levels of untreated groups. *p < 0.05, **p < 0.01, ***p < 0.001.
